MLN-Eo with rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2
Myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and rearrangements involving the tyrosine kinases (TK) PDGFRA, PDGFRB, FGFR1 or presence of a PCM1-JAK2 fusion are rare specific diseases. Clinical and hematologic manifestation is influenced by the partner gene involved in the rearrangement. Eosinophilia is characteristic but not necessarily present.
Classification of MLN-Eo with TK fusion
The neoplasms with eosinophilia and PDGFRA (4q12), PDGFRB (5q31-33), FGFR1 (8p11), or PCM1-JAK2 rearrangement are grouped as a separate entity in the 2017 WHO classification, with MLN-Eo with PCM1-JAK2 rearrangement t(8;9)(p22;p24.1) defined as a new provisional entity.
All share constitutive activation of a tyrosine kinase with a highly heterogeneous clinical presentation. While PDGFRA, PDGFRB, FGFR1 rearrangements involve activation of a receptor tyrosine kinase, the PCM1-JAK2 rearrangement involves constitutive activation of Janus kinase 2 (JAK2), a non-receptor tyrosine kinase. Other rearrangements involving JAK2 (e.g., ETV6-JAK2 and BCR-JAK2) do not currently lead to classification into this specific entity according to WHO.
Essentially, two phases of disease can be distinguished for myeloid/lymphoid neoplasms with eosinophilia and TK fusion: the chronic phase and the blast phase. In the chronic phase, the disease usually presents as MPN or MDS/MPN. In the blast phase, it presents as an acute leukemia (AML, ALL, or MPAL (Mixed-Phenotype Acute Leukemia)) and/or extramedullary disease (e.g., myeloid sarcoma, lymphoma) (Gerds et al. 2020). In contrast, the term accelerated phase is not clearly defined in MLN-Eo with TK fusion (Gerds et al. 2020).
WHO classification 2017 (Swerdlow et al. 2017)
Myeloid/lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, FGFR1 rearrangement or with PCM1-JAK2.
Myeloid/lymphoid neoplasm with PDGFRA rearrangement
Myeloid/lymphoid neoplasm with PDGFRB rearrangement
Myeloid/lymphoid neoplasm with von FGFR1 rearrangement
Provisional entity: myeloid/lymphoid neoplasm with PCM1-JAK2
Overview of MLN-Eo with TK fusion
Table 1: Overview of genetic alterations, clinical presentation and treatment options in myeloid and lymphoid neoplasms with eosinophilia and tyrosine kinase fusion
(according to Arber et al. 2016, updated data on fusion partners according to Reiter & Gotlib 2017, Wang et al. 2020 and Atlas of Genetics and Cytogenetics in Oncology and Haematology)
Cryptic deletion of 4q12-
Response to TKI
t(5;12)(q33;p13); ETV6-PDGFRB, > 30 known partner genes
Response to TKI
Possible response to JAK2-inhibition
Common: PDGFRA and PDGFRB rearrangements
The most common PDGFRA rearrangement observed is the FIP1L1-PDGFRA rearrangement, which results from a submicroscopic deletion in the long arm of chromosome 4, del(4)(q12q12) (Cools et al. 2003). This change is not visible in chromosome band analysis. However, deletion of the CHIC2 gene can be detected by FISH and the resulting FIP1L1-PDGFRA rearrangement by PCR (Gotlib et al. 2004). Rarely, PDGFRA rearrangements with another partner gene occur. These cases, as well as rarely occurring activating PDGFRA mutations, are also encompassed by the WHO category (Swerdlow et al. 2017).
Several fusion partners have been described in the literature for PDGFRB. The most common translocation occurs at t(5;12)(q33;p13), where the oncogene ETV6 fuses with PDGFRB (Cross & Reiter 2002). ETV6-PDGFRB rearrangements can be detected by FISH and RT-PCR. Screening for rare PDGFRB rearrangements is possible by FISH, although chromosome band analysis is usually required for accurate partner determination. RNA sequencing has also recently become available to search for partner genes. Excluded from this WHO entity are Philadelphia-like ALL associated fusions such as EBF1-PDGFRB, SSBP2-PDGFRB, TNIP1-PDGFRB, ZEB2-PDGFRB, ATF7IP-PDGFRB (Swerdlow et al. 2017).
FGFR1 rearrangement (8p11 syndrome)
FGFR1 rearrangements result from a fusion of the FGFR1 gene (in chromosomal band 8p11, hence the name "8p11 syndrome") with a variety of fusion partners, 15 are known to date (Wang et al. 2020). The 8p11 syndrome is clinically characterized by eosinophilia and an association with T-lymphoblastic lymphomas as well as a high transformation rate to acute leukemias. Cytogenetically, a translocation t(8;13)(p11;q12) is usually found, which leads to a ZNF198-FGFR1 rearrangement at the molecular level (Cross & Reiter 2002). These diseases show no response to 1st- and 2nd-generation tyrosine kinase inhibitors, but in vitro data suggest inhibition of chimeric FGFR1 fusion kinases by ponatinib (Ren et al. 2013). One patient with BCR-FGFR1-positive mixed-phenotype acute leukemia (MPAL) achieved a response to combination therapy consisting of chemotherapy followed by ponatinib administration (Khodadoust et al. 2016). Currently, a Phase II trial (Fight-203) is evaluating monotherapy with the FGFR inhibitor pemigatinib. Initial interim results show good response rates. Among the 10 patients with at least one treatment response study, a clinical response (complete or partial remission) was observed in 8 of the 10 patients, this was accompanied by a complete or partial cytogenetic response (Verstovsek et al. 2018). The study is still in the recruitment phase (see also Therapy).
Rare: PCM1-JAK2 rearrangements and other fusions
Myeloid and lymphoid neoplasms with eosinophilia and PCM1-JAK2 rearrangement occur rather rarely. The translocation t(8;9)(p22;p24) is the cause here (Reiter et al. 2005). Other rare rearrangements involving JAK2 as well as ABL1 and FLT3 have been described in MLN-Eo but are not included in the WHO definition (Gerds et al. 2020). Differential diagnosis for rare JAK2 fusions as well as ABL1 fusions should include Philadelphia-like ALL (Swerdlow et al. 2017, Gerds et al. 2020). In patients with PCM1-JAK2 or JAK2, ABL1, and FLT3 fusions, consideration should be given to treatment with a directed tyrosine kinase inhibitor (Gerds et al. 2020, Schwaab et al. 2020). For example, patients with chronic eosinophil leukemia (CEL) and PCM1-JAK2 rearrangement have already shown a response to treatment with ruxolitinib (Reiter et al. 2005, Liermann et al. 2012, Patterer et al. 2013, Rumi et al. 2013 & 2015). Recent data on ruxolitinib therapy in 9 patients with JAK2 fusion show a response (at least complete hematologic remission (CHR)) in 5 of 9 patients. Based on current data, the response appears to be transient, with only one patient achieving a long-lasting (>24 months) CHR. However, ruxolitinib treatment should be considered as a bridge to allogeneic stem cell transplantation (Schwaab et al. 2015 & 2020).
Diagnostics of MLN-Eo with TK fusion
Prognosis of MLN-Eo with TK fusion
Good therapeutic response in neoplasms with eosinophilia and PDGFRA and PDGFRB rearrangements.
Regardless of the partner gene, the detection of PDGFRA rearrangements is of great importance from a therapeutic point of view, as these usually show a good response to treatment with tyrosine kinase inhibitors (Cools et al. 2003). In particular, for FIP1L1-PDGFRA rearrangement, it has been shown that deep molecular and long-lasting remissions are achieved in a large proportion of patients (>90-95%) (Onkopedia Guideline Myeloid Neoplasms with Eosinophilia 2020). Initial, mostly retrospective, studies are currently evaluating whether, analogous to a TKI stop in CML, discontinuation of imatinib treatment is possible (Klion et al. 2007, Gerds et al. 2020, Metzgeroth et al. 2020). Imatinib stop has been described in the literature in a total of 42 patients, 21 of whom experienced molecular or hematologic relapse (Metzgeroth et al. 2020). Re-initiation of imatinib treatment rapidly restored remission in the vast majority of patients (Metzgeroth et al. 2020).
A similarly good therapeutic response to tyrosine kinase inhibitors and long-term remissions were observed in patients with PDGFRB rearrangements (Cheah et al. 2014). No data are currently available on TKI stop in this patient group (Gerds et al. 2020, Onkopedia Guideline Myeloid Neoplasms with Eosinophilia 2020).
Study on the use of the FGFR inhibitor pemigatinib in neoplasms with eosinophilia and FGFR1 rearrangement.
For patients with MLN-Eo and FGFR1 rearrangement, treatment with the FGFR1 inhibitor pemigatinib may be available in a phase II trial. Initial interim results showed a response in 80% of patients (Verstovsek et al. 2018). Further information on study design, inclusion criteria, and study protocol is available at ClinicalTrials.gov and on the homepage of the Leukemia Competence Network. An overview of participating German study centers and contact information can be found here.
High transformation rate to AML in PCM1-JAK2 rearrangement and 8p11 syndrome
Myeloid and lymphoid neoplasms with eosinophilia and PCM1-JAK2 rearrangement or FGFR1 rearrangement (8p11 syndrome) show a high transformation rate to acute leukemias.
Recommendation for MLN-Eo with TK fusion
In case of clinical and cytomorphological suspicion of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 rearrangement, comprehensive screening by cytogenetics and molecular genetics should be performed for diagnosis both for classification according to WHO and because of the immense therapeutic consequences.
Due to the rarity of these disorders, inclusion in the Registry of Patients with Rare Myeloid Neoplasms (German language) may be recommended.